Genocea Biosciences is harnessing the power of the T cell immunity to develop the next generation of vaccines. T cells are increasingly recognized as a critical element of a protective immune response to a wide range of infectious disease pathogens, but are difficult to target using traditional vaccine discovery methods.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/10/12 | $30,000,000 | Series C |
Auriga Partners Bill & Melinda Gates Foundation CVF Cycad Group Johnson & Johnson Innovation Lux Capital Morningside Group MP Healthcare Venture Management Polaris Partners SR One | undisclosed |
